The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GLUE | +70.3% | N/A | N/A | -33% |
| S&P | +11% | +85.61% | +13.15% | +55% |
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $12.77M | 38.5% |
| Gross Profit | $10.67M | 50.0% |
| Gross Margin | 83.59% | 6.4% |
| Market Cap | $457.64M | 40.7% |
| Market Cap / Employee | $3.11M | 27.3% |
| Employees | 147 | 10.5% |
| Net Income | -$27.08M | -13.5% |
| EBITDA | -$30.88M | -26.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $208.34M | 65.9% |
| Accounts Receivable | $9.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $35.93M | -10.3% |
| Short Term Debt | $4.24M | 16.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 5.41% | 47.5% |
| Return On Invested Capital | -66.57% | 17.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $99.78M | 566.4% |
| Operating Free Cash Flow | $100.43M | 578.4% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 69.05 | 13.14 | 24.26 | - | |
| Price to Book | 2.07 | 1.28 | 1.01 | 1.71 | 17.92% |
| Price to Sales | 5.64 | 2.41 | 2.08 | 3.36 | -88.41% |
| Price to Tangible Book Value | 2.07 | 1.28 | 1.01 | 1.71 | 17.92% |
| Price to Free Cash Flow TTM | 11.23 | 12.63 | 15.54 | 4.21 | - |
| Enterprise Value to EBITDA | 6.47 | 2.19 | -9.03 | -8.40 | -13.10% |
| Free Cash Flow Yield | 8.9% | 7.9% | 6.4% | 23.8% | - |
| Return on Equity | -36.2% | 2.9% | 9.8% | 9.3% | -115.16% |
| Total Debt | $42.72M | $41.86M | $41.13M | $40.17M | -8.08% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
